Form 4: Bionano Genomics Director, Yvonne Linney, Acquires 30,000 Stock Options

Yvonne Linney, a director at Bionano Genomics, acquired 30,000 stock options on June 18, 2024, according to a recent SEC filing.

Summary

• On June 18, 2024, Yvonne Linney, a director of Bionano Genomics, acquired 30,000 stock options.
• The exercise price of these options is $0.7752.
• The options vest in equal monthly installments over 12 months, with full vesting by the next annual stockholder meeting, contingent on continuous service.
• The options also vest fully upon a Change of Control as defined in the company's 2018 equity incentive plan.
• The options expire on June 18, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director. While insider ownership can be a positive signal, this is a standard compensation practice.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It's common for directors and officers to receive stock options as part of their compensation.

Stakeholder Impact

• The acquisition of stock options by a director could potentially increase shareholder confidence.

Key Dates

Keywords

Bionano Genomics, Director, Stock Options, Acquisition, SEC Filing, BNGO, Vesting, Equity Incentive Plan